Benzinga | May 19, 2021 07:46AM EDT

JMP Securities Maintains Market Outperform on Iovance Biotherapeutics, Lowers Price Target to $43

JMP Securities analyst Reni Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and lowers the price target from $45 to $43.